10 x Reta

For research purposes only, this product is not intended for human consumption, diagnosis, or treatment. It has not been approved by the FDA or MHRA. Sales are limited to qualified researchers and institutions, and misuse could lead to account termination or legal consequences.

Reta is the nickname for retatrutide, a triple-agonist peptide injection designed to promote weight loss by targeting three hormone pathways.
Reta, also known as retatrutide or reta peptide, is a once-weekly injectable medication developed by Eli Lilly for the treatment of obesity and overweight conditions. It is a triple hormone receptor agonist, meaning it simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple action helps regulate appetite, metabolism, and blood sugar levels, making it more potent than earlier drugs like semaglutide (Ozempic) or tirzepatide (Mounjaro), which target one or two receptors.